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Monoclonal antibody (MAb) 6-11A directed against Streptococcus mutans surface adhesin P1 was shown
previously to influence the mucosal immunogenicity of this organism in BALB/c mice. The specificity of anti-P1
serum immunoglobulin G (IgG) and secretory IgA antibodies and the subclass distribution of anti-P1 serum IgG
antibodies were altered, and the ability of elicited serum antibodies to inhibit S. mutans adherence in vitro was in
certain cases increased. MAb 6-11A is known to recognize an epitope dependent on the presence of the proline-rich
region of the protein, although it does not bind directly to the isolated P-region domain. In this report, we show that
MAb 6-11A recognizes a complex discontinuous epitope that requires the simultaneous presence of the alanine-rich
repeat domain (A-region) and the P-region. Formation of the core epitope requires the interaction of these segments
of P1. Residues amino terminal to the A-region also contributed to recognition by MAb 6-11A but were not essential
for binding. Characterization of the MAb 6-11A epitope will enable insight into potential mechanisms of immuno-
modulation and broaden our understanding of the tertiary structure of P1.
Systemic and mucosal immunization with an antigen bound
by a monoclonal antibody (MAb) has been used to elicit hu-
moral immunity against poorly immunogenic epitopes (7, 39,
45, 47, 48, 62, 66). Immunomodulation by antibodies is a strat-
egy that can be used to deliberately shift reactivity away from
immunodominant but nonprotective epitopes toward subdomi-
nant but more protective epitopes (1, 6, 25, 35, 37, 69). We
have identified a MAb, 6-11A, that recognizes the P1 surface
adhesin of Streptococcus mutans. When MAb 6-11A is bound
to P1 on the bacterial surface prior to mucosal immunization
of BALB/c mice, the elicited humoral immune response is
substantially altered (12).
S. mutans has been implicated as a major etiologic agent of
human dental caries (19, 34). The 185,000-Mr surface protein
of S. mutans serotype c organisms is widely believed to mediate
adherence to the salivary tooth pellicle and is variously re-
ferred to in the literature as antigen I/II (51), antigen B (52),
P1 (15), and PAc (41). Data supporting a role for humoral
immunity against human dental caries have been reported for
many years. Immunization with P1 or parts thereof (18, 32, 54,
57, 67) or with S. mutans whole cells (8, 31) has been shown to
prevent S. mutans adherence in vitro and colonization of the
tooth surface and development of dental caries in animal
models. Passive immunization studies with immunoglobulin G
(IgG) antibodies against antigen I/II have also been shown to
prevent caries in humans (34a) and nonhuman models (33).
As reviewed by Jenkinson and Demuth (23), the proteins of
the antigen I/II family have all similar sizes (1,500 to 1,566
amino acids) and contain an amino-terminal signal sequence, a
series of alanine-rich tandem repeats within the amino-termi-
nal third of the molecule, a 150-residue variable region where
most sequence variations between the P1 and PAc sequences
are clustered (10), a series of proline-rich tandem repeats in
the central portion of the molecule, and a carboxy-terminal
sequence characteristic of wall- and membrane-spanning do-
mains of streptococcal surface proteins, including the LPXTG
motif involved in cell wall anchorage (53). A schematic repre-
sentation of P1 is shown in Fig. 1. Members of the antigen I/II
family are produced by most species of oral streptococci (23)
and comprise multiple ligand binding sites (24). Discrete re-
gions within these proteins are believed to interact with host
tissue components, including salivary glycoproteins, calcium,
collagen, laminin, keratin, fibronectin, and other microbial
cells, and certain of these interactions appear to involve com-
plex nonlinear structures (10, 17). A panel of MAbs was pre-
viously generated against P1 (5), and the binding sites of 11
unique MAbs were approximated based on reactivity with full-
length and truncated P1 polypeptides (9, 10, 14, 49).
The immunomodulatory MAb 6-11A is one of four anti-P1
MAbs that do not bind directly to the isolated P-region but
whose binding depends on the presence of this domain (9).
The immunomodulatory effects of MAb 6-11A vary depending
on the route of mucosal immunization and on the coating
concentration of the antibody (12). Coating S. mutans with
anti-P1 MAb 6-11A prior to mucosal immunization of mice
results in notable changes in the specificity and subclass distri-
bution of serum IgG antibodies. The specificity of the mucosal
secretory IgA antibody response is similarly influenced by this
MAb (50). Sera from mice immunized by gastric intubation
with bacteria coated with MAb 6-11A are more inhibitory of
S. mutans adherence to human salivary agglutinin than those
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from mice immunized with bacteria alone, indicating that
changes in the antibody response are associated with changes
in potential biological activity.
Serum IgG antibodies against P1 from mice immunized with
S. mutans and S. mutans coated with MAb 6-11A recognized
antigenic determinants dependent on the presence of the P-
region (50), a segment necessary for the structural integrity,
stability, and surface expression of the molecule (9). These sera
are not reactive with the isolated P-region (12), again suggest-
ing the involvement of this domain in the formation of complex
epitopes not achieved within many partial recombinant P1
polypeptides (9, 50, 59).
The binding of MAb 6-11A to P1 on the surface of S. mutans
alters P1’s susceptibility to proteolytic digestion in vitro (50).
This suggests that a change of protein conformation and hence
potential differences in antigen processing and presentation
may contribute to the immunomodulatory effects of this MAb
and influence the spectrum of antibodies elicited during a
polyclonal response (29, 36, 38, 55). The location and physical
character of the epitope for MAb 6-11A would be expected to
yield information regarding the potential mechanism(s) of im-
munomodulation by MAb 6-11A. This work demonstrates that
both the A- and P-regions are necessary to reconstitute the
epitope recognized by MAb 6-11A. A segment of P1, consist-
ing of amino acid residues 84 to 190, which is directly upstream
of the A-region, was also demonstrated to contribute to the
complex discontinuous epitope recognized by this MAb.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. Serotype c S. mutans
strain NG8 was used as previously described (50). Escherichia coli host strains
DH5, JM109, and TOP10 were grown aerobically at 37°C with vigorous shaking
in Luria-Bertani broth ( LB; 1% [wt/vol] tryptone, 0.5% [wt/vol] yeast extract, 1%
[wt/vol] NaCl) supplemented with ampicillin (50 to 100 g/ml). Plasmid pCR2.1-
TOPO (Invitrogen Corp., San Diego, Calif.) was used as a cloning vector, and
pMal-p (New England Biolabs, Inc., Beverly, Mass.) and pBAD (Invitrogen
Corp.) were used as cloning and expression vectors.
Anti-P1 monoclonal and polyclonal antibodies. Anti-P1 MAbs (5) were affinity
purified from murine ascites fluid with a protein A cartridge and the BioLogic
HR workstation (Bio-Rad, Hercules, Calif.), dialyzed against phosphate-buffered
saline (PBS, pH 7.2) containing 0.3% sodium azide, aliquoted, and stored at
20°C. Rabbit polyclonal antiserum 216 was made against P1 isolated by ion-
exchange and gel filtration chromatography (11). Antiserum 220 was made
against S. mutans NG8 whole cells (9) and rendered monospecific for P1 by
exhaustive adsorption with the spaP-negative mutant PC3370 (13).
PCR amplification and construction of spaP subclones. Amplification and
construction of P1 polypeptides MA3 (amino acids 819 to 1017), MA41 (amino
acids 185 to 472), NR1 (amino acids 465 to 963), NR2 (amino acids 465 to 1218),
NR3 (amino acids 816 to 1218), and NR4 (amino acids 465 to 1561) were
previously described (9, 14, 50). These polypeptides were expressed as fusion
proteins with maltose binding protein (MBP). Other sequences of interest within
spaP were amplified by PCR with forward and reverse primers based on the
published spaP sequence (28). The forward and reverse primers used to generate
NR5 (amino acids 84 to 190) were 5-CAAATGGTTCATACCATTGAAGTA
CC-3 and 5-GCGTTCAACCTCGGCTTT-3, respectively. DNA encoding
NR6 (amino acids 84 to 472) was amplified with the forward primer for NR5 and
the reverse primer 5-GGGAATTCTCAGTCAGTCACTTAACTGGATAGTC
TGCTA-3 (italics indicate an engineered EcoRI site).
The PCR for NR5 used pDC20 (9) as the template and was carried out for 30
cycles under the following conditions: (i) denaturation at 94°C for 30 s; (ii)
primer annealing at 54°C for 1 min; and (iii) primer extension at 72°C for 20 s.
The PCR for NR6 used NG8 chromosomal DNA as the template and was carried
out for 35 cycles under the following conditions: (i) denaturation at 94°C for 30 s;
(ii) primer annealing at 50°C for 1 min; and (iii) primer extension at 72°C for 1
min. Final primer extensions were carried out for an additional 7 min after the
last cycle. Amplified PCR products were cloned into pBAD (Invitrogen Corp.)
according to the manufacturer’s instructions. The sequence of each spaP sub-
clone was confirmed by the University of Florida’s DNA Sequencing Core. A
schematic representation of P1 and recombinant P1 polypeptides used in this
study is shown in Fig. 1.
SDS-PAGE and Western immunoblot analysis of recombinant P1 polypep-
tides. Recombinant E. coli harboring vector alone or plasmids encoding P1-MBP
fusion proteins NR1, NR2, NR3, and NR4 (50) were grown overnight in 5 ml of
LB containing 50 g of ampicillin per ml. Cultures were diluted 1:50 into fresh
LB-ampicillin (2 ml) and grown to an optical density (600 nm) of 0.5. Cells were
induced with IPTG (isopropyl--D-thiogalactopyranoside) to a final concentra-
tion of 0.3 mM for 2 h. Cells were harvested by centrifugation at high speed for
10 min with a tabletop microcentrifuge and resuspended in 200 l of sodium
dodecyl sulfate (SDS) sample buffer. Samples were boiled for 5 min and centri-
fuged for 5 min prior to analysis by polyacrylamide gel electrophoresis (PAGE)
and Western immunoblotting.
FIG. 1. Schematic representation of S. mutans P1, including known structural domains. Recombinant polypeptides encoded by spaP subclones
with corresponding amino acid residue numbers and location on the linear protein sequence are indicated.
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Each of the P1-MBP fusion polypeptides was separated on 7.5% polyacryl-
amide slab gels under nonreducing conditions and electroblotted onto nitrocel-
lulose. A phosphate extract from S. mutans known to contain P1 (10) was in-
cluded as a positive control on each gel. Replicate nitrocellulose blots were
stained with colloidal gold (Diversified Biotech, Boston, Mass.), with MAb 6-11A
diluted 1:1,000, or with a cocktail of anti-P1 polyclonal rabbit antisera 216 and
220, each diluted 1:1,000. Expression of each fusion protein was confirmed with
anti-MBP polyclonal rabbit antibody (New England Biolabs) diluted 1:10,000.
Affinity-purified peroxidase-labeled goat anti-mouse immunoglobulin (ICN/
Cappell ICN Biomedicals, Aurora, Ohio) diluted 1:2,000 and affinity-purified
peroxidase-labeled goat anti-rabbit IgG (ICN/Cappell) diluted 1:1,000 were used
as secondary reagents. Development was with 4-chloro-1-naphthol solution (7 ml
of PBS, 1 ml of 4-chloro-1-naphthol [Sigma; 3 mg/ml in ice-cold methanol], and
8 l of 30% hydrogen peroxide).
Proteolytic treatment of MAb-coated S. mutans and recovery of liberated MAb
and bound peptide. S. mutans was harvested from 50 ml of an overnight culture by
centrifugation and coated with MAb 6-11A as previously described (50). Bacteria
were preincubated with MAb, washed free of unbound MAb, and treated with buffer
alone or with 50 g of endoproteinase Arg-C (Sigma, St. Louis, Mo.) in 1 ml of 100
mM Tris-HCl–10 mM CaCl2, pH 7.6, incubated for 60 h at 37°C. Bacteria were
pelleted at high speed for 5 min in a tabletop microcentrifuge, and the supernatant
was removed and boiled for 5 min in SDS sample buffer. Cell pellets were also
resuspended and boiled in SDS sample buffer.
Products of digestion present in cell-free supernatants or associated with
bacterial pellets were separated on 10 or 7.5% polyacrylamide slab gels under
reducing and nonreducing conditions and electroblotted onto nitrocellulose.
Replicate blots were stained with colloidal gold (Diversified Biotech) or reacted
with affinity-purified peroxidase-labeled goat anti-mouse immunoglobulin (H
and L chain) (ICN/Cappell) diluted 1:2,000 and developed with a 4-chloro-1-
naphthol solution as described above.
Following proteolysis, goat anti-mouse immunoglobulin-agarose beads (Sigma)
were used to recover MAb 6-11A from cell-free supernatants according to the
manufacturer’s instructions. Beads were equilibrated with 0.01 M sodium phosphate
buffer (PBS, pH 7.2) containing 0.5 M NaCl. One milliliter of the supernatant
fraction of MAb 6-11A-coated S. mutans digested with endoproteinase Arg-C was
incubated with 250 l of goat anti-mouse immunoglobulin-agarose beads for 1 h at
room temperature. The beads were allowed to settle, and buffer containing unbound
material was removed. Beads were washed three times with 1 ml of 0.01 M PBS, pH
7.2, containing 0.5 M NaCl. All washes were collected and analyzed to ensure that
MAb 6-11A was not removed from the beads. The presumed immune complex
consisting of MAb 6-11A and bound P1 fragments was eluted from the affinity beads
with 200 l of 0.5 M acetic acid–0.15 M NaCl, pH 2.4. This collection step was
repeated four times. The presence of MAb in elution fractions was confirmed by
SDS-gel electrophoresis and Western immunoblotting with peroxidase-conjugated
anti-mouse immunoglobulin. As controls, untreated MAb 6-11A and MAb treated
with endoproteinase Arg-C were bound and eluted from the goat anti-mouse im-
munoglobulin-agarose beads and tested as described above.
MALDI-TOF mass spectrometry analysis of affinity-purified MAb and bound
peptide. Elution fractions from the goat anti-mouse immunoglobulin-agarose
beads containing MAb 6-11A and any bound P1 peptide(s) were analyzed by
matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass
spectrometry (MS) with the Voyager-SUPER DE STR instrument (Applied
Biosystems, Framingham, Mass). MALDI/MS analyses of samples were per-
formed in the positive linear mode with an accelerating voltage of 25 kV, a grid
voltage of 93%, and a delay time of 350 ns. All analyses in the positive-ion mode
were performed with a saturated solution of -cyano-4-hydroxycinnamic acid in
water-ethanol-formic acid (45:45:10, vol/vol) as the matrix. Control samples
included untreated and protease endoproteinase Arg-C-treated MAb, bound
and eluted from the goat anti-mouse immunoglobulin-agarose beads at concen-
trations similar to that recovered from MAb-coated bacteria.
ELISA analysis of P1 sequences contributing to recognition by MAb 6-11A.
E. coli harboring plasmids pMA3, pMA41, pNR1, pNR2, pNR3, pNR4, pNR5,
pNR6, or the pMal-p or pBAD vector-only controls were grown and recombi-
nant proteins were expressed according to the manufacturers’ instructions (New
England Biolabs and Invitrogen Corp). Cell lysates were prepared by harvesting
bacteria by centrifugation, washing and resuspending them in 50 mM Tris buffer,
pH 7.5, and sonicating them with four 20-s blasts at 20% output power with
cooling on ice between blasts. Cell debris was removed by centrifugation at high
speed in a tabletop microcentrifuge for 30 min at 4°C. Expression of recombinant
P1-MBP fusion proteins was confirmed by Western blot analysis and detection
with anti-MBP polyclonal rabbit antiserum. Expression of polypeptides NR5 and
NR6 was confirmed with anti-V5 polyclonal mouse antiserum (Invitrogen Corp.)
or the A-region-specific anti-P1 MAb 3-8D (14), respectively. Total protein levels
in the soluble sonic extracts were quantified with the bicinchoninic acid protein
assay kit (Sigma) with bovine serum albumin as the standard. The presence of
comparable levels of recombinant P1 polypeptides in the cell lysates was con-
firmed by serial-titration enzyme-linked immunosorbent assay (ELISA) with
anti-MBP and anti-P1 antibodies as appropriate.
To determine whether binding of MAb 6-11A was achieved upon interaction
of individual P1 polypeptides, Costar High Binding ELISA plates (Corning
Incorporated, Corning, N.Y.) were coated with 200 ng of cell lysate containing the
indicated recombinant protein in 0.1 M carbonate-bicarbonate buffer, pH 9.6, over-
night at 4°C. Plates were blocked with PBS, pH 7.2, containing 0.25% Tween 20 and
0.2% sodium azide for 2 h at room temperature and washed, and 100 l of twofold
serial dilutions starting at 100 ng of total protein/well of cell lysate containing a
second recombinant P1 polypeptide was added to the wells, and wells were incu-
bated overnight at 4°C. Plates were washed, and MAb 6-11A diluted 1:1,000 was
applied to the wells and incubated at 4°C overnight. After washing, MAb binding was
detected with affinity-purified peroxidase-labeled goat anti-mouse immunoglobulin
(H and L chains) (ICN/Cappell) diluted 1:2,000. Plates were developed with 0.01 M
phosphate citrate buffer containing 0.1 M o-phenylenediamine dihydrochloride and
0.012% hydrogen peroxide, and absorbance was read at 450 nm. Wells coated with
full-length P1 and with lysates from E. coli harboring vector only were included as
positive and negative controls on each plate. Successful coating of comparable levels
of individual recombinant P1 polypeptides was confirmed with anti-P1, anti-MBP, or
anti-V5 antibodies as appropriate.
RESULTS
Reactivity of MAb 6-11A with defined recombinant P1
polypeptides. Using truncated and full-length recombinant P1
polypeptides, Brady et al. (10) previously localized a segment
of P1 contributing to binding by MAb 6-11A to the central
region of the molecule. To further characterize the epitope,
reactivity with the products of spaP subclones spanning the
central and central-carboxy-terminal regions of P1, including
NR1 (amino acids 465 to 963), NR2 (amino acids 465 to 1218),
NR3 (amino acids 816 to 1218), and NR4 (amino acids 465 to
1561), was tested by Western immunoblot (Fig. 2). A sche-
matic representation of the locations of these polypeptides is
shown in Fig. 1. Each P1-MBP recombinant protein was reac-
tive with anti-MBP polyclonal rabbit antiserum (Fig. 2A) and
with anti-P1 polyclonal antisera (Fig. 2B). Liberation of the P1
moiety from the MBP fusion partner by digestion with factor
Xa did not result in recognition by MAb 6-11A (data not
shown). MAb 6-11A did not bind directly to any of the P1
polypeptides, including NR4, which encompasses the central-
carboxy-terminal two-thirds of the protein (Fig. 2C). This sug-
gested that its epitope likely includes additional sequences not
contained within amino acids 465 to 1561.
Copurification of MAb 6-11A and bound P1 fragment fol-
lowing proteolysis of MAb-coated S. mutans. When bound to
P1 on the cell surface, immunomodulatory MAb 6-11A influ-
ences the susceptibility of the protein to numerous proteases in
vitro (50). When S. mutans coated with MAb 6-11A was treated
with enodoproteinase Arg-C, it was observed that a high-molec-
ular-weight band disappeared from the bacterial cell surface and
appeared in the cell-free supernatant fractions (49). The band was
not recognized by polyclonal anti-P1 or -S. mutans antisera (data
not shown) and was identified as immunoglobulin with affinity-
purified goat anti-mouse IgG antibody (Fig. 3). A replicate gel
and Western blot run under reducing conditions confirmed the
presence of bands corresponding to the molecular size of IgG
heavy and light chains (data not shown).
Because the MAb itself was resistant to proteolysis by en-
doproteinase Arg-C, it was reasoned that cleavage of P1 re-
sulted in release of the antibody from the bacterial surface.
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This suggested the utility of an epitope excision approach to
further characterize the 6-11A epitope. In this method, a na-
tive antigen is bound by antibody prior to proteolytic digestion,
thus enabling identification and characterization of linear as
well as discontinuous epitopes (20). Therefore, to capture
MAb 6-11A and any P1 fragment still bound to it, the cell-free
supernatant fraction of endoproteinase Arg-C-treated MAb-
coated bacteria was passed over goat anti-mouse immunoglob-
ulin-agarose beads. SDS-PAGE and Western immunoblot
analysis were used to monitor the elution of MAb 6-11A from
the affinity beads (Fig. 4). MAb 6-11A was detected in the
supernatant starting material and in elution fractions 1 through
4, but not in the flowthrough material or wash fractions (Fig.
4B). As a basis for comparison to ensure that the MAb itself
was not altered during proteolysis, and as a positive control for
affinity purification, MAb 6-11A alone and endoproteinase
Arg-C-treated MAb were passed over the beads and eluted as
described in Materials and Methods (data not shown).
Identification of P1 peptide by MALDI/MS. Elution frac-
tions containing MAb 6-11A with a possible recovered P1
fragment and the MAb 6-11A control alone were analyzed by
MALDI/MS. A MALDI/MS spectrum of MAb 6-11A alone
passed over the goat anti-mouse immunoglobulin-agarose
beads showed no peaks in the lower-molecular-weight range
(data not shown). However, a relatively broad singly charged
ion with an average observed Mr (Mrobs) of 11,780 (calculated
Mr  11,830) was observed within the spectrum from the first
elution fraction off of the goat anti-mouse immunoglobulin
immunoaffinity beads (Fig. 5). The broad nature of the peak
FIG. 2. Confirmation of expression of recombinant P1 polypep-
tides by Western immunoblot. Cell lysates of E. coli harboring plas-
mids encoding P1-MBP fusion polypeptides NR1, NR2, NR3, and
NR4 were separated on SDS–7.5% polyacrylamide slab gels under
nonreducing conditions and electroblotted onto nitrocellulose. A ly-
sate of E. coli harboring the pMal-p vector only was included as a
negative control, and a phosphate extract of S. mutans containing P1
was included as a positive control. Replicate blots were reacted with
anti-MBP polyclonal rabbit antisera (A), anti-P1 polyclonal rabbit
antisera (B), or MAb 6-11A (C).
FIG. 3. SDS-PAGE and Western immunoblot analysis following
endoproteinase Arg-C treatment of S. mutans coated with MAb 6-11A.
Products of digestion associated with the bacterial pellet and present in
the cell-free supernatant were separated on SDS-polyacrylamide slab
gels under nonreducing conditions, electroblotted onto nitrocellulose,
and stained with colloidal gold (A) or reacted with peroxidase-labeled
goat anti-mouse immunoglobulin (H and L chain) (B). The arrow
indicates MAb 6-11A released following enzymatic treatment.
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might potentially result from glycosylation, although P1 is not
believed to be glycosylated. Alternatively, varying degrees of
oxidation of the eluted peptide during handling or an effect of
desorption of the peptide from the beads may account for the
broad peak. Based on the known amino acid sequence of P1,
the peptide size detected for this ion corresponds to a pre-
dicted cleavage fragment generated by endoproteinase Arg-C
digestion of P1 and maps to amino acid residues 84 to 190
(Table 1). This amino acid sequence resides directly up-
stream of the alanine-rich tandem repeats. The ion corre-
sponding to that with an Mrobs of 5,937 (calculated Mr 
5,915) was interpreted to represent the doubly charged ion of
the putative peptide and the other ion at an Mrobs of 3,441 was
FIG. 4. Affinity purification of MAb 6-11A from cell-free supernatant following endoproteinase Arg-C treatment of S. mutans coated with MAb
6-11A. Proteins present in the cell-free supernatant starting material and in the flowthrough, wash, and elution fractions following passage over
goat anti-mouse IgG-agarose beads were separated by SDS-PAGE under nonreducing conditions, electroblotted onto nitrocellulose, and stained
with colloidal gold (A) or reacted with peroxidase-labeled goat anti-mouse immunoglobulin (H and L chains) (B).
FIG. 5. MALDI/MS spectrum of singly and doubly charged ions of
material associated with affinity-purified MAb 6-11A released from
antibody-coated S. mutans with endoproteinase Arg-C. The asterisk
indicates an ion that could not be identified.
TABLE 1. Predicted products of digestion following cleavage of
P1 at arginine residues by endoproteinase Arg-C,
listed in order of molecular weighta
Fragment size








































a Boldface type indicates the P1 fragment putatively identified by MALDI/MS
analysis.
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interpreted to be due to interference. Corresponding elution
fractions of MAb alone or supernatants from endoproteinase
Arg-C-treated bacteria alone did not contain any peptide
peaks in this mass range (data not shown).
ELISA to detect contributions of P1 segments to binding by
MAb 6-11A. The dependency of MAb 6-11A on the P-region of
P1 (9), its lack of reactivity with P1 polypeptides spanning the
central- and carboxy-terminal regions of P1 (Fig. 2), and the
MALDI/MS identification of a putative P1 peptide corre-
sponding to amino acids 84 to 190 (Fig. 5 and Table 1) sug-
gested that MAb 6-11A’s epitope may consist of multiple dis-
connected sequences of the protein. To test this hypothesis,
additive ELISAs were performed with combinations of recom-
binant P1 polypeptides. In the first of these experiments,
ELISA plate wells were coated with P-region-containing
polypeptides NR4 and MA3. A-region-containing polypep-
tides MA4, NR6, and NR5, corresponding to the peptide iden-
tified by MALDI analysis, were reacted with the immobilized
moieties prior to assessment of MAb 6-11A binding (Fig. 6A
and B). As had been observed by Western immunoblotting,
MAb 6-11A did not react directly with any of the individual P1
polypeptides by ELISA (data not shown). MAb 6-11A binding
was detected when the polypeptide corresponding to the A-re-
gion, MA41, was overlaid on either of the P-region-containing
fragments, NR4 (Fig. 6A) or MA3 (Fig. 6B). MAb 6-11A
binding was greatest when NR6, which corresponds to the
A-region and the upstream sequence identified by MALDI,
was reacted with immobilized MA3 or NR4. MAb 6-11A did
not bind when the NR5 peptide was reacted with MA3 or NR4.
The addition of E. coli negative-control lysates harboring the
pMal-p or pBAD vector to immobilized polypeptide MA3 or
NR4 had no effect on MAb 6-11A reactivity.
FIG. 6. Restoration of MAb 6-11A binding by additive ELISA. E. coli cell lysates containing recombinant P1 polypeptides NR4 (A) or MA3
(B) were immobilized on ELISA plate wells and subsequently incubated with serial dilutions (beginning at 100 ng of protein/well) of E. coli cell
lysates containing recombinant P1 polypeptide NR5, NR6, or MA41 or the pMal-p or pBAD vector as negative controls. The degree of restoration
of binding of MAb 6-11A was detected with peroxidase-conjugated goat anti-mouse IgG. Panels C and D illustrate MAb 6-11A binding when the
order of addition of the P1 polypeptides was reversed. E. coli cell lysates containing recombinant polypeptide NR5, NR6, or MA41 or vector-only
negative controls were immobilized and incubated with serial dilutions of E. coli cell lysates containing NR4 (C) or MA3 (D).
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ELISAs in which MA41, NR6, or NR5 was immobilized and
MA3 or NR4 was overlaid prior to assessment of MAb 6-11A
binding were also performed (Fig. 6C and D). Again, no re-
activity was observed with the individual immobilized polypep-
tides. The addition of NR5 or vector-only controls had no
effect on MAb 6-11A reactivity. The addition of either NR4
(Fig. 6C) or MA3 (Fig. 6D) to immobilized MA41 or NR6
resulted in detectable binding by 6-11A, but reactivity was not
restored to the same extent as when these P-region-containing
fragments were used to coat the wells (Fig. 6A and B). This
suggests that the majority of contact residues may lie near or
within the A-region. Hence, these may be more accessible
when either MA41 or NR6 is added to immobilized NR4 or
MA3 and masked when either MA3 or NR4 is added to im-
mobilized MA41 or NR6. Addition of NR6 to immobilized
MA3 and NR4 also resulted in higher binding of MAb 6-11A
than did addition of MA41, but the effect was not as pro-
nounced as when NR4 and MA3 were immobilized.
The detection of MAb 6-11A reactivity following interaction
of the isolated A- (MA41) and P-regions (MA3) indicates that
such an interaction is required for the formation of the core
epitope recognized by this antibody. The higher binding of
MAb 6-11A following interaction with P-region-containing
polypeptides of NR6, which spans both the peptide identified
by MALDI/MS and the A-region (amino acids 84 to 472),
compared to the A-region alone (amino acids 185 to 472),
suggests that the complete epitope recognized by this MAb
also involves amino acids contained within residues 84 to 190
of P1. The positional effect observed when amino-terminal
versus central-carboxy-terminal polypeptides were immobi-
lized is also consistent with MAb 6-11A binding predominantly
in proximity to the A-region.
DISCUSSION
Murine MAb 6-11A against the surface protein P1 of S. mu-
tans (5, 11) modulates the humoral immune response to S. mu-
tans when live S. mutans bacteria coated with the MAb are
used as the immunogen (12). Compared to S. mutans alone,
MAb-coated S. mutans triggered an in vivo humoral immune
response which was more inhibitory of S. mutans adherence to
salivary agglutinin and differed in epitope specificity against P1
(12, 50). There are two major mechanisms through which an-
tibodies contained in immune complexes can affect an adaptive
immune response against antigen in the complex. The first
involves the Fc portion of the antibody molecule and Fc re-
ceptors on antigen-presenting cells and can be independent of
epitope specificity (2–4, 37, 46). The second depends on epi-
tope specificity and may result from blockage of specific anti-
genic sites on the antigen, steric hindrance, changes in acces-
sibility of antigenic determinants by bound antibody, and/or
conformational changes in the three-dimensional structure of
the antigen induced by antibody binding (4, 36, 61). Changes in
susceptibility of a protein to proteolytic degradation are an
indication of an alteration in its conformation (21, 27, 60, 63).
The facts that MAb 6-11A-mediated immunomodulation re-
sults in the production of antibodies that are more inhibitory of
S. mutans adherence to salivary agglutinin and influences the
protease digestion of P1 (50) suggest that its binding to P1 may
increase the response against cryptic or nondominant epitopes.
In light of the effects of MAb 6-11A on the immunogenicity of
P1, characterization of its epitope would be helpful in eluci-
dating the potential mechanism of immunomodulation and in
gaining an understanding of the tertiary structure of P1.
Experiments were undertaken to evaluate MAb 6-11A reac-
tivity with recombinant partial P1 polypeptides and combina-
tions thereof. In addition, a P1 peptide was copurified with
MAb 6-11A after protease digestion of antibody-coated bac-
teria and identified by MALDI/MS. The data derived from
these experiments indicate that the epitope recognized by
MAb 6-11A is complex and discontinuous in nature. It is con-
tributed to by segments of P1 encompassing the A-region, the
sequence amino-terminal to the A-region, and the P-region,
suggesting that these discontinuous sequences are in close
proximity to one another in the native protein. MAb 6-11A
does not bind to A- or P-region fragments alone (9, 14) or to
recombinant P1 with either of these regions deleted (9, 14, 54),
indicating that both segments are required simultaneously to
establish the appropriate epitope configuration.
An epitope recognized by 6-11A was reconstituted by inter-
actions of A- and P-region polypeptides corresponding to
amino acids 185 to 472 and 819 to 1017. Residues contained
within amino acids 84 to 190 immediately upstream of the
A-region also contributed to recognition by the MAb. In ad-
dition, increased restoration of MAb 6-11A binding when A-
containing fragments were overlaid on immobilized P-region-
containing fragments suggests the presence of important
contact residues within the A-region. The binding of two dis-
continuous amino acid segments of a P1 homolog, SpaA of
Streptococcus sobrinus, to form an immunodominant confor-
mational epitope similar if not identical to that on the native
protein was first described by Goldschmidt et al. (16). More
recently, it was also reported that the anti-antigen I/II MAb
Guy’s 13 binds to a determinant dependent on the interaction
between two discontinuous A- and P-region-containing seg-
ments (59). However, in ELISA experiments described by
these investigators, recognition by Guy’s 13 did not appear to
be influenced by which fragment was immobilized on the plate.
The suggested close proximity of the A- and P-regions within
the native molecule is supported by crystallography of the in-
tervening variable region. Troffer-Charlier et al. (58) published
the crystal structure of a segment of antigen I/II of S. mutans
serotype f spanning the last eight amino acids of the A-region
through the first 18 amino acids of the P-region. They describe
the topology of this domain as a distorted -sandwich made up
of two sheets of eight anti-parallel -strands each and report
that the solvent-exposed arm of the N-terminal helix (A-re-
gion) and the extended C-terminal peptide (P-region) lie on
the same side of the -sandwich. This information supports an
A- and P-region interaction within the native molecule that
would achieve the tertiary structure of the epitope recognized
by MAb 6-11A. However, additive ELISA experiments de-
scribed above indicate that the intervening variable sequence
between the A- and P-regions is not necessary for these do-
mains to interact in a configuration compatible with MAb
6-11A binding.
The fortuitous finding that intact MAb 6-11A was released
from the surface of S. mutans by endoproteinase Arg-C digestion
(50) suggested the utility of epitope excision (20) to identify por-
tions of P1 in contact with the MAb. Since an antibody itself is
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relatively resistant to limited protease digestion (22, 56), polypep-
tide sequences comprising or in close proximity to contact resi-
dues are protected from proteolysis. Such a footprinting approach
has been used in combination with MALDI/MS to characterize
both linear (26, 30, 42–44, 64, 65, 68) and discontinuous (20)
epitopes of various antigens. The peptide that copurified with
MAb 6-11A after protease cleavage of P1 from antibody-coated
bacteria apparently contributes to a discontinuous epitope in
which the A-region and P-region of P1 are absolutely required for
this MAb binding. Whereas deletion of the A- or P-region com-
pletely eliminated MAb 6-11A reactivity, deletion of residues 90
to 186 did not (data not shown). However, the contribution of P1
residues 84 to 190 to an optimal epitope structure is supported by
additive ELISA experiments.
Capture of peptide comprising amino acids 84 to 190 with
MAb 6-11A after protease cleavage of cell-associated P1 illus-
trates the ability of the antigen binding site within an anti-
body to retain a portion of a more complete epitope follow-
ing proteolysis. Conversely, monoclonal antibodies are
sometimes capable of binding individual peptide fragments
that contribute to discontinuous conformational epitopes. As
reviewed by Mumey et al. (40), this is the basis behind an
epitope mimetic phage display technique for elucidating spa-
tial proximity information of the molecular surfaces of pro-
teins that are refractory to conventional approaches, such as
X-ray diffraction. However, MAb 6-11A did not react with
recombinant P1 peptide comprising amino acids 84 to 190
alone by Western immunoblotting, in direct ELISA, or in
competition ELISA against whole P1 (data not shown), even
though protein footprinting, MALDI/MS, and additive ELISA
experiments clearly demonstrate the contribution of the
pre-A-region sequence to MAb 6-11A binding. That this
isolated portion of the epitope was not recognized out of
context underscores the benefit in certain cases of epitope
excision compared to the more traditional epitope extraction
approach, in which the antigen of interest is first digested
enzymatically before being reacted with immobilized antibody
for capture of reactive fragments (20).
The identification and mapping of discontinuous epitopes on
a protein such as S. mutans adhesion P1 provides insight into
the structure of the molecule. Since P1 is a promising target of
protective immunity against dental caries, information about
its three-dimensional topography is relevant for rational vac-
cine design. The native structure of P1 likely contributes to the
biological function of P1, including its interaction with human
salivary agglutinin (11, 17) as well as its stability and translo-
cation to the S. mutans cell surface (9, 54). Compared to other
anti-P1 MAbs, 6-11A is weak in its ability to directly inhibit
adherence of S. mutans to immobilized salivary agglutinin (11).
The fact that immunomodulation by MAb 6-11A results in an
antibody response more inhibitory of S. mutans adherence to
agglutinin (50) suggests that its binding to cell-associated P1
prior to immunization may expose or stabilize an agglutinin
binding domain resulting in enhanced immunogenicity of as-
sociated epitopes. In addition, other mechanisms such as Fc-
mediated uptake by antigen-presenting cells and alterations in
isotype or avidity of elicited antibodies may also contribute to
immunomodulation by MAb 6-11A.
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